Navigation Links
Low dose of targeted drug might improve cancer-killing virus therapy
Date:6/16/2014

COLUMBUS, Ohio Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Viruses that are designed to kill cancer cells oncolytic viruses have shown promise in clinical trials for the treatment of brain cancer and other solid tumors. This cell and animal study suggests that combining low doses of the drug bortezomib with a particular oncolytic virus might significantly improve the ability of the virus to kill cancer cells during oncolytic virus therapy.

The research is published in the journal Clinical Cancer Research.

"These findings pave the way for a treatment strategy for cancer that combines low doses of bortezomib with an oncolytic virus to maximize the efficacy of the virus with little added toxicity," says principal investigator Balveen Kaur, PhD, professor and vice chair of research, Department of Neurological Surgery and Radiation Oncology, and a member of the OSUCCC James Translational Therapeutics Program.

"Because bortezomib is already approved by the Food and Drug Administration, a clinical trial could be done relatively quickly to test the effectiveness of the drug-virus combination," Kaur says.

Bortezomib inhibits the activity of proteasomes, structures in cells that break down and recycle proteins. Kaur notes that blocking these "cellular recycling plants" activates a cellular stress response and increases the expression of heat shock proteins. This reaction, which can lead to bortezomib resistance, makes the cells more sensitive to oncolytic virus therapy with little additional toxicity.

For this study, Kaur and her colleagues used a herpes simplex virus-type 1 oncolytic virus. Key technical findings include:

  • One of the overexpressed heat-shock proteins, HSP90, facilitates oncolytic virus replication, enabling the virus to kill more tumor cells;
  • In a glioma model, the combination treatment suppressed tumor growth by 92 percent relative to controls and improved survival (six of eight tumors had completely regressed by day 23 after treatment);
  • Similar outcomes occurred in a head and neck cancer model.

"To our knowledge, this study is the first to show synergy between an oncolytic HSV-1-derived cancer killing virus and bortezomib," Kaur says. "It offers a novel therapeutic strategy that can be rapidly translated in patients with various solid tumors."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related biology news :

1. New research could provide key to overcoming resistance to HER2 targeted cancer treatments
2. New Penn-designed gel allows for targeted therapy after heart attack
3. Cancer therapy may be too targeted
4. Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer
5. Scientists uncover image of muscular dystrophy defect & design targeted drug candidates
6. Targeted synthesis of natural products with light
7. Targeted treatment can significantly reduce relapse in children with AML leukemia
8. Fruit pest targeted by genomic research
9. Researchers use nanoscale patches to sensitize targeted cell receptors
10. Targeted culling of deer controls disease with little effect on hunting
11. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... The leading ... of its most experienced veterinary clients have treated over 100 of their own patients ... technology to provide the highest level of care for their patients. , The ...
(Date:5/19/2016)... (PRWEB) , ... May 19, 2016 , ... Anton Paar ... 30,000 square foot office building is complete. The new structure adds a third office ... Anton Paar USA purchased 2.4 acres of land, along with office space ...
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
Breaking Biology Technology: